Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.
![](https://o2hventures.com/wp-content/uploads/2019/05/portfolio-content-image-1.jpg)
![](https://o2hventures.com/wp-content/uploads/2019/05/portfolio-content-image-2.jpg)
![](https://o2hventures.com/wp-content/uploads/2019/05/portfolio-content-image-3.jpg)
Status | Active |
Website | https://www.exonate.com/ |
Category | Biotech |
Modality | Small Molecule |
Headquaters | Cambridge, UK |
Partner | Johnson and Johnson |
Investment Portfolio | Fund Investment |
Co-Investors | The University Of Nottingham Parkwalk, Angel Cofund, Wren Capital University of Bristol Enterprise Fund |